U.S. FDA Will Give Takeda's Alogliptin A Second Chance With New Study Design
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Takeda Pharmaceutical will make a fresh stab at obtaining U.S. FDA approval for alogliptin, a selective dipeptidyl peptidase IV inhibitor for type 2 diabetes, after receiving a FDA nod for the study design of a cardiovascular outcomes trial, the company said
You may also be interested in...
Bristol/AstraZeneca Roll Out Onglyza Post-Market Cardio Study
The Phase IV commitment to study cardio risk is part of saxagliptin's approval, but the partners are also looking for data to support a claim of cardioprotective effect.
Bristol/AstraZeneca Roll Out Onglyza Post-Market Cardio Study
The Phase IV commitment to study cardio risk is part of saxagliptin's approval, but the partners are also looking for data to support a claim of cardioprotective effect.
Takeda Gets Second Chance With U.S. FDA Complete Response On Actos Combo Drug
Osaka-based Takeda Pharmaceutical stated this week that it has received a complete response letter from U.S. FDA; the American drug regulator stated in the letter that the NDA review for a fixed-dose alogliptin and Actos (pioglitazone) combo drug will depend on additional data from a cardiovascular safety study FDA requested for the company's alogliptin monotherapy NDA